HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

“Devil Is In The Details” On Prop 65 Reform Benefits – AHPA

This article was originally published in The Rose Sheet

Executive Summary

California Gov. Jerry Brown wants to cap attorney fees and settlement funds in Prop 65 cases and require expanded plaintiff disclosures and demonstrations of supporting evidence before litigation can proceed, among other proposed measures designed to reduce frivolous lawsuits against industry members.

You may also be interested in...



Cosmetics Firms Held “Hostage” By Prop 65 Litigators; Law Changes Possible

Proposition 65 lawsuits have increased for the cosmetics industry with the expiration of a grace period for new ingredients added to California’s list of substances linked to cancer or reproductive toxicity. Attorneys from Edwards Wildman offer perspective on the issue and its impact on industry.

Prop 65 Litigators Turning Sights On Beauty Industry, Lawyer Says

Prop 65 suits tend to hit industries in waves, and there are indications that the beauty industry is next, says Angela Diesch, attorney for Sacrament, Calif.-based Greenberg Traurig. Marketers of products containing methyl eugenol, lead or cocamide DEA should ensure they are complying with the California law.

Waiting For FDA Intervention On Prop 65? Don’t Hold Your Breath

Arbitrary or not, California's enforcement of Proposition 65 is likely to continue undeterred, with FDA currently in no position to intervene, experts say

Related Content

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018520

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel